High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition

High-throughput proteomic profiling provides a comprehensive analysis of systemic cancer effects and tumor microenvironment interactions. Characterizing soluble proteins driving inflammation in acute myeloid leukemia (AML) offers insight into inflammatory diseases like differentiation syndrome related to AML therapies like menin inhibitors. We present our application of nucleic acid-linked immuno-sandwich assay, a novel technology leveraging next-generation sequencing for high-throughput, ultrasensitive characterization of secreted inflammatory proteins in plasma or serum. Here, we report its use to identify dynamic soluble protein changes during treatment and at the time of suspected differentiation syndrome in pediatric AML patients treated with the menin inhibitor revumenib (NCT04065399 and NCT05360160).